25 reports

Monoclonal antibodies such as mepolizumab and omalizumab are sometimes effective.

  • Cough And Cold
  • China
  • Demand
  • Market Size
  • Trade

Monoclonal antibodies such as mepolizumab and omalizumab are sometimes effective.

  • Cough And Cold
  • China
  • Demand
  • Market Size
  • GlaxoSmithKline plc

Pasteur Institute NA NA MONOCLONAL ANTIBODY TO ANTAGONIZE FCGRIIA FOR AUTOIMMUNE ARTHRITIS, PULMONARY INFLAMMATION, SYSTEMIC ANAPHYLAXIS AND THROMBOCYTOPENIA - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description

  • Cough And Cold
  • Therapy
  • United States
  • World
  • Product Initiative

SUMMARY CHRONIC KIDNEY DISEASE MONOCLONAL ANTIBODIES MONOCLONAL ANTIBODIES Monoclonal antibody therapy uses monoclonal antibodies (mAb) to bind to target cells or proteins that is used in the treatment of various diseases.

  • Renal Disease
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles

The molecules developed by Companies in Phase I, IND/ CTA Filed and Preclinical stages are ##, ## and ## respectively.

  • Chronic Disease
  • Renal Disease
  • United States
  • World
  • Novartis AG
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017

Anti-neutrophil cytoplasmic auto-antibody (ANCA) -associated vasculitis (AAV).

  • Renal Disease
  • Therapy
  • United States
  • Product Initiative
  • ChemoCentryx, Inc.

It is a fully human HuCAL-based antibody developed based on HuCAL technology.

  • Renal Disease
  • Therapy
  • United States
  • World
  • CTI BioPharma Corp.
  • AB-023 - DRUG PROFILE
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018 (CONTD..2), H2 2018

THE DRUG CANDIDATE IS A REPURPOSED MONOCLONAL ANTIBODY.

  • Diabetes
  • Renal Disease
  • United States
  • Company
  • Product Initiative

Most recently she served as the Worldwide Brand Director at Novartis Pharmaceuticals Corporation, where she was the global launch lead for Aimovig®, the first monoclonal antibody approved by the U. S.

  • Cough And Cold
  • HIV AIDS
  • Renal Disease
  • United States
  • AcelRx Pharmaceuticals, Inc.

The drug candidate is a monoclonal antibody that inhibits binding of IL-## to the ST## receptor.

  • Cough And Cold
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • R&D Progress
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..2), H1 2018

THE MONOCLONAL ANTIBODY IS ADMINISTERED THROUGH INTRAVENOUS ROUTE AND TARGETS CX##CR##.

  • Cell Therapy
  • Renal Disease
  • United States
  • Company
  • Product Initiative

It also develops a product candidate, an anti-CD## monoclonal antibody that inhibits the production of adenosine produced by the tumor cells.

  • Cough And Cold
  • Pharmaceutical
  • Therapy
  • United States
  • Vernalis plc
  • Stage of Development

Cellmid develops CAB##, a humanized monoclonal antibody for use in solid tumors; CAB##, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK##, a recombinant human form of MK protein for use in cardiac ischem

  • Molecular Diagnostics
  • Pathology
  • Pharmaceutical
  • Renal Disease
  • Therapy

Cellmid develops CAB##, a humanized monoclonal antibody for use in solid tumors; CAB##, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK##, a recombinant human form of MK protein for use in cardiac ischem

  • Genitourinary System Disease
  • Renal Disease
  • United States
  • Product Initiative
  • Angion Biomedica Corp.
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

" Although vaccination to prevent hepatitis B infection has been standard practice for decades for dialysis patients and healthcare workers, there remains a need to provide improved overall protection safely through a greater and more durable antibody response, " said Robert Janssen

  • Clinical Trial
  • Cough And Cold
  • Monoclonal Antibody
  • Renal Disease
  • World
  • POLYCYSTIC KIDNEY DISEASE - PIPELINE BY KADMON CORP LLC, H1 2018
  • POLYCYSTIC KIDNEY DISEASE - PIPELINE BY IC-MEDTECH INC, H1 2018

The company' s discovery platforms include metabolomics, chromics, monoclonal antibodies, synthetic biology and gene regulation.

  • Renal Disease
  • Therapy
  • United States
  • Company
  • Product Initiative

Boehringer Sohn AG & Co KG ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Biogen Inc Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2018 2018 trials are taken as

  • Monoclonal Antibody
  • Renal Disease
  • Therapy
  • World
  • Merck & Co., Inc.
  • Renal Diseases, Global, Pipeline Programs Targeting
  • Renal Diseases, Global, Co-development Deals by Molecule Type, 2006-2017

There are only a small number of other molecule types - such as monoclonal antibodies (mAb) and proteins - available in the market.

  • Chronic Disease
  • Pathology
  • Renal Disease
  • Deals & Alliance
  • Galectin Therapeutics Inc.

CELLMID LIMITED HAS SIGNED A COLLABORATION AGREEMENT WITH ANTITOPE LTD (CAMBRIDGE, UK) FOR THE HUMANIZATION OF ITS LEAD THERAPEUTIC MONOCLONAL ANTIBODY CANDIDATE.

  • Genitourinary System Disease
  • Renal Disease
  • United States
  • Product Initiative
  • Quark

Hoffmann-La Roche Ltd Roche Glycart AG Biogen Idec Ltd; Chugai Pharmaceutical Co Ltd; Genentech Inc R& D Progress Research and Development Brief Obinutuzumab (Gazyva, Gazyvaro) is a glycoengineered, fully humanized IgG## monoclonal antibody with anti-neoplastic activity.

  • Pharmaceutical
  • Renal Disease
  • United States
  • World
  • CTI BioPharma Corp.
  • POLYCYSTIC KIDNEY DISEASE - PIPELINE BY IPSEN SA, H2 2018
  • POLYCYSTIC KIDNEY DISEASE - PIPELINE BY KADMON CORP LLC, H2 2018

The company' s discovery platforms include metabolomics, chromics, monoclonal antibodies, synthetic biology and gene regulation.

  • Renal Disease
  • Therapy
  • United States
  • Company Operations
  • Product Initiative

MorphoSys AG (Morphosys) is a pharmaceutical company that develops monoclonal antibodies for therapeutic, diagnostic and research applications.

  • Chronic Disease
  • Genitourinary System Disease
  • Pharmaceutical
  • Renal Disease
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Chronic Disease
  • Clinical Trial
  • Cough And Cold
  • Renal Disease
  • World
  • R&D Progress
  • WNT-001 - DRUG PROFILE

The therapeutic candidate is humanized monoclonal antibody which acts by targeting LRP##.

  • Chronic Disease
  • Genitourinary System Disease
  • Renal Disease
  • United States
  • Product Initiative

The company" s product portfolio includes vaccines and antibody therapeutics with focus on infectious diseases, autoimmune diseases and cancer.

  • Anesthetics
  • Clinical Trial
  • Cough And Cold
  • Pharmaceutical
  • Opiant Pharmaceuticals, Inc.